Reported 4 months ago
The article discusses how forecasts for annual global sales of weight-loss drugs, particularly from Novo Nordisk and Eli Lilly, have been raised to around $150 billion by the early 2030s due to increasing supplies, potential broader usage, and a growing number of competitors. This jump in forecasts from the previous estimate of $100 billion is driven by the rising demand for these medications, with millions seeking access to them. Insurers currently do not cover the drugs extensively, leading many individuals to pay out of pocket or use coupons from drug manufacturers. Despite ongoing supply constraints, sales are expected to climb as manufacturing capacity increases.
Source: YAHOO